Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Lindhurst, Marjorie J ^a   Yourick, Miranda R ^a   Yu, Yi ^b   Savage, Ronald E ^b   Ferrari, Dora ^b   Biesecker, Leslie G ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b ARQULE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPYRIDINE DERIVATIVE; BECAPLERMIN; IMIDAZOLE DERIVATIVE; MIRANSERTIB; PLATELET DERIVED GROWTH FACTOR B; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR;

CELL CULTURE; CELL SURVIVAL; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MULTIPLE CANCER; MUTATION; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

AMINOPYRIDINES; CELL SURVIVAL; CELLS, CULTURED; HUMANS; IMIDAZOLES; MUTATION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEUS SYNDROME; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-SIS; SIGNAL TRANSDUCTION;

EID: 84949007638     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17162     Document Type: Article

References (25)

1. Biesecker, L. G. The Multifaceted Challenges of Proteus Syndrome. JAMA 285, 2240-2243 (2001).
2. Carpten, J. D. et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448, 439-444 (2007).
3. Lindhurst, M. J. et al. A Mosaic Activating Mutation in AKT1 Associated with the Proteus Syndrome. New Engl. J. Med. 365, 611-619 (2011).
4. Malamitsi-Puchner, A., Dimitriadis, D., Bartsocas, C. & Wiedemann, H. R. Proteus Syndrome: Course of a Severe Case. Am. J. Med. Genet. 35, 283-285 (1990).
5. Iqbal, J. et al. Case Report:Morphological Characterization of the Breast in Proteus Syndrome Complicated by Ductal Carcinoma In Situ. Ann. Clin. Lab. Sci. 36, 469-474 (2006).
6. Turner, J. T., Cohen, M. M., Jr. & Biesecker, L. G. Reassessment of the Proteus syndrome literature: Application of diagnostic criteria to published cases. Am. J. Med. Genet. 130A, 111-122 (2004).
7. Slavotinek, A. M., Vacha, S. J., Peters, K. F. & Biesecker, L. G. Sudden death caused by pulmonary thromboembolism in Proteus syndrome. Clin. Genet. 58, 386-389 (2000).
8. Landgraf, K. E., Pilling, C. & Falke, J. J. Molecular Mechanism of an Oncogenic Mutation That Alters Membrane Targeting: Glu17Lys Modifies the PIP Lipid Specificity of the AKT1 PH Domain. Biochemistry 47, 12260-12269 (2008).
9. Parikh, C. et al. Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers. Proc. Natl. Aca. Sci., USA 109, 19368-19373 (2012).
10. Manning, B. D. & Cantley, L. C. AKT/PKB Signaling: Navigating Downstream. Cell 129, 1261-1274 (2007).
11. Yu, Y. et al. In vitro and in vivo anti-tumor activity of ARQ 092, a potent and selective pan-AKT inhibitor. Eur. J. Cancer 50, 172-173 (2014).
12. Kovacina, K. S. Identification of a Proline-rich Akt Substrate as a 14-3-3 Binding Partner. J. Biol. Chem. 278, 10189-10194 (2003).
13. Kaidanovich-Beilin, O. & Woodgett, J. R. GSK-3: functional insights from cell biology and animal models. Front. Mol. Neurosci. 4, 1-25 (2011).
14. Wang, Y., Zhou, Y. & Graves, D. T. FOXO Transcription Factors: Their Clinical Significance and Regulation. BioMed Res. Int. 2014, 1-13 (2014).
15. Danial, N. N. BAD: undertaker by night, candyman by day. Oncogene 27, S53-S70 (2009).
16. Meyuhas, O. Physiological roles of ribosomal protein S6: One of its kind. in International Review of Cell and Molecular Biology 268, 1-37 (Elsevier, 2008).
17. Fenton, T. R. & Gout, I. T. Functions and regulation of the 70 kDa ribosomal S6 kinases. Int. J. Biochem. Cell Biol. 43, 47-59 (2011).
18. Kohler, N. & Lipton, A. Platelets as a source of fibroblast growth-promoting activity. Exp. Cell Res. 87, 297-301 (1974).
19. Andrae, J., Gallini, R. & Betsholtz, C. Role of platelet-derived growth factors in physiology and medicine. Gene. Dev. 22, 1276-1312 (2008).
20. Franke, T. F. et al. The Protein Kinase Encoded by the Akt Proto-Oncogene Is a Target of the PDGF-Activated Phosphatidylinositol 3-Kinase. Cell 81, 727-736. (5AD).
21. Crouch, S. P. M., R, K., J, S. K. & Fletcher, J. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J. Immunol. Methods 160, 81-88 (1993).
22. Saleh, M. et al. First-in-human study with ARQ 092, a novel pan AKT-inhibitor, in subjects with advanced solid tumors or recurrent malignant lymphoma. Eur. J. Cancer 50, 104 (2014).
23. Sankhala, K. et al. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target. Oncol. 4, 135-142 (2009).
24. Lindhurst, M. J. et al. AKT1 Gene Mutation Levels Are Correlated with the Type of Dermatologic Lesions in Patients with Proteus Syndrome. J. Invest. Dermatol. 134, 543-546 (2013).
25. Lindhurst, M. J. et al. Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nat. Genet. 44, 928-933 (2012).